Developer docs
API playgroundTry for free, no card

Search company profiles

Cardior Pharmaceuticals

Full company profile

uuid0000lm1

Namestring
Cardior Pharmaceuticals
Legal namestring
Cardior Pharmaceuticals GmbH
Websiteurl
cardior.de
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Hannover, Germany, founded in 2017 by Prof. Thomas Thum to develop non-coding RNA (ncRNA)-based therapeutics for cardiovascular disease. The company's scientific platform centers on microRNA (miRNA) biology, with its lead asset CDR132L being a synthetic antisense oligonucleotide designed to inhibit miR-132 — a microRNA implicated in pathological cardiac remodeling and heart failure progression. The pipeline extends beyond CDR132L (currently in the 280-patient HF-REVERT Phase 2 trial across 60+ European sites) to include preclinical candidate CDR348T and discovery-stage programs.

The company's business model is that of a clinical-stage biotech with no commercial therapeutic product revenue. Pre-acquisition revenue mechanics consisted of non-dilutive grant funding (including a €1.01M grant in 2018) and equity capital raised across a ~€15M Series A (2017) and a €64M Series B (2021). Cardior also commercialized a CE-marked in-vitro diagnostic — the CardiorHealth miR-132 PCR Kit — which provides a modest complementary revenue stream and a translational biomarker tool for patient stratification. Following its acquisition by Novo Nordisk in May 2024 for up to €1.025 billion, Cardior operates as a wholly-owned subsidiary of Novo Nordisk Region Europe A/S, with its development programs advancing under the acquirer's cardiovascular pipeline strategy.

Short descriptiontext

Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company developing non-coding RNA-based therapeutics for cardiovascular disease. Its lead asset CDR132L, a miR-132 inhibitor, is in Phase 2 trials for heart failure; it was acquired by Novo Nordisk in 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHanover, Germany
HQ citystring
Hanover
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA-based therapeutics, cardiac disease treatment, heart failure drugs, oligonucleotide therapeutics, non-coding RNA platform
Industry3 codes
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cardiovascular Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biotech, Cardior's revenue model centers on developing novel RNA-based therapeutics through clinical trials toward regulatory approval and commercial launch. The company was acquired by Novo Nordisk in March 2024 for €1.025 billion, making it a wholly-owned subsidiary, with future revenue expected from drug commercialization in cardiovascular indications.

openpr.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Prior to acquisition, Cardior operated with funding from venture capital and milestone-based financing. Thomas Thum has filed over 40 patents, nine of which have been successfully licensed to pharma companies currently in Phase 1/2 clinical development.

cardior.de
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cardior Pharmaceuticals discovers and develops non-coding RNA (ncRNA)-based therapeutics designed to prevent, repair and reverse diseases of the heart. Its lead product CDR132L is an oligonucleotide-based inhibitor of miR-132 that halts and reverses detrimental cardiac remodeling in heart failure patients following myocardial infarction, currently evaluated in the Phase 2 HF-REVERT clinical trial. The company also markets a CE-marked companion diagnostic PCR kit (CardiorHealth miR-132 PCR Kit) to measure circulating miR-132 levels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 1b study showed favorable safety profile and beneficial cardiac effects in heart failure patients treated with CDR132L vs placebo
+3 more records
Product overview1 text field

Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the discovery and development of non-coding RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company's core product is CDR132L, an oligonucleotide-based miRNA-132 inhibitor currently in Phase 2 clinical trials (HF-REVERT) for post-myocardial infarction heart failure. The therapeutic pipeline includes CDR348T (preclinical, hypertrophic cardiomyopathy), CDR641L (discovery stage), and an undisclosed program for diverse indications. Additionally, Cardior developed the CardiorHealth miR-132 PCR Kit, a CE-marked companion diagnostic that measures miR-132 levels in patient blood. The company was acquired by Novo Nordisk in May 2024 for up to €1.025 billion.

Product and service4 records
1CDR132L
CategoryCore therapeutic candidate
Description

An oligonucleotide-based inhibitor directed against miRNA-132 (miR-132), designed to halt and reverse detrimental cardiac remodeling following myocardial infarction. First-ever ncRNA-based therapy to enter clinical trials in heart disease, currently in Phase 2 (HF-REVERT).

2CDR348T
CategoryPipeline therapeutic candidate
Description

Preclinical therapeutic program targeting hypertrophic cardiomyopathy through modulation of non-coding RNAs.

3CDR641L
CategoryPipeline therapeutic candidate
Description

Discovery-stage therapeutic program targeting cardiac diseases through interaction with non-coding RNAs.

4CardiorHealth miR-132 PCR Kit
CategoryDiagnostic product
Description

CE-marked PCR diagnostic kit that measures circulating microRNA-132 (miR-132) levels in patient blood. Used as a companion diagnostic in the HF-REVERT Phase 2 Clinical Study to monitor CDR132L therapy.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-12-11
Description

Cardior received €1.01 million grant for joint research project with IMTTS to identify novel oligonucleotides for treatment of chronic heart failure. Prof. Thomas Thum serves as Director of IMTTS.

cardior.de
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing gene therapies and regenerative medicines for heart disease, including heart failure and cardiomyopathies. Highly comparable to Cardior as a modality-focused, clinical-stage cardiovascular company targeting similar patient populations with a novel mechanism of action.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on cardiovascular diseases, including cardiac diseases caused by genetic mutations. Directly comparable to Cardior in mission (cardiac disease modification) and stage (early-to-mid clinical development with a novel modality).

TypeDirect peer
Description

Clinical-stage company developing in vivo gene editing therapies for cardiovascular disease, with lead programs in atherosclerotic cardiovascular disease. Comparable to Cardior as a modality-disruptive cardiovascular biotech targeting root-cause biology rather than symptomatic treatment.

TypeDirect peer
Description

Late-stage cardiovascular biopharmaceutical company developing cardiac myosin modulators for heart failure and hypertrophic cardiomyopathy. Comparable to Cardior in therapeutic area (heart failure and HCM) and clinical-stage drug development focus.

TypeBroad incumbent
Description

Developed cardiac disease-modifying therapies for HCM and DCM and was acquired by BMS for $13.1B. Relevant benchmark as a successful cardiovascular biotech exit in a closely related indication space where Cardior's CDR348T also targets HCM.

TypeBroad incumbent
Description

Established commercial-stage RNAi therapeutics company with a broad pipeline across multiple therapeutic areas. Relevant as the leading commercial RNA-interference platform, providing technical and strategic benchmarks for Cardior's oligonucleotide-based ncRNA approach.

TypeBroad incumbent
Description

Pioneer in antisense oligonucleotide (ASO) RNA-targeted therapeutics with multiple approved and clinical-stage assets. Highly comparable technology platform to Cardior's oligonucleotide-based miRNA inhibition and a relevant strategic comparator.

TypeBroad incumbent
Description

Clinical-stage RNAi therapeutics company with broad pipeline including cardiovascular and cardiometabolic programs. Comparable modality (RNAi-based) and clinical-stage development model to Cardior.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company with cardiovascular programs including therapies for heart failure and rare cardiac diseases. Comparable as a clinical-stage company advancing disease-modifying cardiovascular therapeutics.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing treatments for heart failure and other cardiometabolic conditions. Comparable as a mid-stage company addressing unmet needs in heart failure, an indication also targeted by Cardior.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cardior Pharmaceuticals

Cardiovascular Biopharmaceuticalscardior.de

Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company developing non-coding RNA-based therapeutics for cardiovascular disease. Its lead asset CDR132L, a miR-132 inhibitor, is in Phase 2 trials for heart failure; it was acquired by Novo Nordisk in 2024.

What Cardior Pharmaceuticals does

Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Hannover, Germany, founded in 2017 by Prof. Thomas Thum to develop non-coding RNA (ncRNA)-based therapeutics for cardiovascular disease. The company's scientific platform centers on microRNA (miRNA) biology, with its lead asset CDR132L being a synthetic antisense oligonucleotide designed to inhibit miR-132 — a microRNA implicated in pathological cardiac remodeling and heart failure progression. The pipeline extends beyond CDR132L (currently in the 280-patient HF-REVERT Phase 2 trial across 60+ European sites) to include preclinical candidate CDR348T and discovery-stage programs.

The company's business model is that of a clinical-stage biotech with no commercial therapeutic product revenue. Pre-acquisition revenue mechanics consisted of non-dilutive grant funding (including a €1.01M grant in 2018) and equity capital raised across a ~€15M Series A (2017) and a €64M Series B (2021). Cardior also commercialized a CE-marked in-vitro diagnostic — the CardiorHealth miR-132 PCR Kit — which provides a modest complementary revenue stream and a translational biomarker tool for patient stratification. Following its acquisition by Novo Nordisk in May 2024 for up to €1.025 billion, Cardior operates as a wholly-owned subsidiary of Novo Nordisk Region Europe A/S, with its development programs advancing under the acquirer's cardiovascular pipeline strategy.

Cardior Pharmaceuticals firmographics

Firmographics
Name
Cardior Pharmaceuticals
Legal name
Cardior Pharmaceuticals GmbH
Website
https://cardior.de
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
11–50 employees
Short description
Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company developing non-coding RNA-based therapeutics for cardiovascular disease. Its lead asset CDR132L, a miR-132 inhibitor, is in Phase 2 trials for heart failure; it was acquired by Novo Nordisk in 2024.
Ownership category
akta.pro rank

Cardior Pharmaceuticals industry classification

Industry
Product category
Cardiovascular Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)

Keywords

  • RNA-based therapeutics
  • Cardiac disease treatment
  • Heart failure drugs
  • Oligonucleotide therapeutics
  • Non-coding RNA platform

Where Cardior Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Hanover
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Cardior Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Development and Commercialization: As a clinical-stage biotech, Cardior's revenue model centers on developing novel RNA-based therapeutics through clinical trials toward regulatory approval and commercial launch. The company was acquired by Novo Nordisk in March 2024 for €1.025 billion, making it a wholly-owned subsidiary, with future revenue expected from drug commercialization in cardiovascular indications.
  2. Licensing and Milestone Payments: Prior to acquisition, Cardior operated with funding from venture capital and milestone-based financing. Thomas Thum has filed over 40 patents, nine of which have been successfully licensed to pharma companies currently in Phase 1/2 clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Cardior Pharmaceuticals product offering

Product offering

Core offering

Cardior Pharmaceuticals discovers and develops non-coding RNA (ncRNA)-based therapeutics designed to prevent, repair and reverse diseases of the heart. Its lead product CDR132L is an oligonucleotide-based inhibitor of miR-132 that halts and reverses detrimental cardiac remodeling in heart failure patients following myocardial infarction, currently evaluated in the Phase 2 HF-REVERT clinical trial. The company also markets a CE-marked companion diagnostic PCR kit (CardiorHealth miR-132 PCR Kit) to measure circulating miR-132 levels.

Product overview

Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the discovery and development of non-coding RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company's core product is CDR132L, an oligonucleotide-based miRNA-132 inhibitor currently in Phase 2 clinical trials (HF-REVERT) for post-myocardial infarction heart failure. The therapeutic pipeline includes CDR348T (preclinical, hypertrophic cardiomyopathy), CDR641L (discovery stage), and an undisclosed program for diverse indications. Additionally, Cardior developed the CardiorHealth miR-132 PCR Kit, a CE-marked companion diagnostic that measures miR-132 levels in patient blood. The company was acquired by Novo Nordisk in May 2024 for up to €1.025 billion.

Differentiator

Problem solved

Functional benefit

Products and services

  • CDR132L An oligonucleotide-based inhibitor directed against miRNA-132 (miR-132), designed to halt and reverse detrimental cardiac remodeling following myocardial infarction. First-ever ncRNA-based therapy to enter clinical trials in heart disease, currently in Phase 2 (HF-REVERT).
  • CDR348T Preclinical therapeutic program targeting hypertrophic cardiomyopathy through modulation of non-coding RNAs.
  • CDR641L Discovery-stage therapeutic program targeting cardiac diseases through interaction with non-coding RNAs.
  • CardiorHealth miR-132 PCR Kit CE-marked PCR diagnostic kit that measures circulating microRNA-132 (miR-132) levels in patient blood. Used as a companion diagnostic in the HF-REVERT Phase 2 Clinical Study to monitor CDR132L therapy.

Quantifiable outcome

  • Phase 1b study showed favorable safety profile and beneficial cardiac effects in heart failure patients treated with CDR132L vs placebo
  • +3 more outcomes

Companies that use Cardior Pharmaceuticals

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Cardior Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cardior Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH)coreStrategic or Co-development Partner · 11 December 2018Cardior received €1.01 million grant for joint research project with IMTTS to identify novel oligonucleotides for treatment of chronic heart failure. Prof. Thomas Thum serves as Director of IMTTS.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Cardior Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Tenaya Therapeutics: Clinical-stage biotech developing gene therapies and regenerative medicines for heart disease, including heart failure and cardiomyopathies. Highly comparable to Cardior as a modality-focused, clinical-stage cardiovascular company targeting similar patient populations with a novel mechanism of action.
  • Lexeo Therapeutics: Clinical-stage gene therapy company focused on cardiovascular diseases, including cardiac diseases caused by genetic mutations. Directly comparable to Cardior in mission (cardiac disease modification) and stage (early-to-mid clinical development with a novel modality).
  • Verve Therapeutics: Clinical-stage company developing in vivo gene editing therapies for cardiovascular disease, with lead programs in atherosclerotic cardiovascular disease. Comparable to Cardior as a modality-disruptive cardiovascular biotech targeting root-cause biology rather than symptomatic treatment.
  • Cytokinetics: Late-stage cardiovascular biopharmaceutical company developing cardiac myosin modulators for heart failure and hypertrophic cardiomyopathy. Comparable to Cardior in therapeutic area (heart failure and HCM) and clinical-stage drug development focus.

Broad incumbents

  • MyoKardia (acquired by Bristol-Myers Squibb): Developed cardiac disease-modifying therapies for HCM and DCM and was acquired by BMS for $13.1B. Relevant benchmark as a successful cardiovascular biotech exit in a closely related indication space where Cardior's CDR348T also targets HCM.
  • Alnylam Pharmaceuticals: Established commercial-stage RNAi therapeutics company with a broad pipeline across multiple therapeutic areas. Relevant as the leading commercial RNA-interference platform, providing technical and strategic benchmarks for Cardior's oligonucleotide-based ncRNA approach.
  • Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) RNA-targeted therapeutics with multiple approved and clinical-stage assets. Highly comparable technology platform to Cardior's oligonucleotide-based miRNA inhibition and a relevant strategic comparator.
  • Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with broad pipeline including cardiovascular and cardiometabolic programs. Comparable modality (RNAi-based) and clinical-stage development model to Cardior.

Emerging players

  • BridgeBio Pharma: Clinical-stage biopharmaceutical company with cardiovascular programs including therapies for heart failure and rare cardiac diseases. Comparable as a clinical-stage company advancing disease-modifying cardiovascular therapeutics.
  • Lexicon Pharmaceuticals: Clinical-stage biopharmaceutical company developing treatments for heart failure and other cardiometabolic conditions. Comparable as a mid-stage company addressing unmet needs in heart failure, an indication also targeted by Cardior.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Cardior Pharmaceuticals social profiles

Digital presence

Cardior Pharmaceuticals compliance and trust

Trust signal

Compliance1 record

Cardior Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cardior Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles1 record

Cardior Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cardior Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardior Pharmaceuticals

What does Cardior Pharmaceuticals do?

Cardior Pharmaceuticals discovers and develops non-coding RNA (ncRNA)-based therapeutics designed to prevent, repair and reverse diseases of the heart. Its lead product CDR132L is an oligonucleotide-based inhibitor of miR-132 that halts and reverses detrimental cardiac remodeling in heart failure patients following myocardial infarction, currently evaluated in the Phase 2 HF-REVERT clinical trial. The company also markets a CE-marked companion diagnostic PCR kit (CardiorHealth miR-132 PCR Kit) to measure circulating miR-132 levels.

Is Cardior Pharmaceuticals a public or private company?

Cardior Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.

When was Cardior Pharmaceuticals founded?

Cardior Pharmaceuticals was founded in 2017. It employs 11 to 50 people.

Where is Cardior Pharmaceuticals based?

Cardior Pharmaceuticals is headquartered in Hanover, Germany, in the Europe region.

How does Cardior Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Development and Commercialization is the primary driver. The others are licensing and Milestone Payments.

Who are Cardior Pharmaceuticals's main competitors?

Direct peers on record are Tenaya Therapeutics, Lexeo Therapeutics, Verve Therapeutics and Cytokinetics. Broad incumbents are MyoKardia (acquired by Bristol-Myers Squibb), Alnylam Pharmaceuticals, Ionis Pharmaceuticals and Arrowhead Pharmaceuticals. Emerging players are BridgeBio Pharma and Lexicon Pharmaceuticals.

Does Cardior Pharmaceuticals have an API?

No public API is recorded for Cardior Pharmaceuticals.

What industry is Cardior Pharmaceuticals in?

Cardior Pharmaceuticals's product category is Cardiovascular Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumNovo Nordisk microRNA drug fluffs its lines in heart failureNovo Nordisk's microRNA drug CDR132L failed to show a statistically significant benefit over placebo in the HF-REVERT heart failure trial. The study of 280 patients found no significant difference in the primary endpoint, though the drug showed some improvement. Novo Nordisk is running other phase 2 trials expected to generate results next year.openPR.comSegment Evaluation and Major Growth Areas in the Myocardial Ischemia MarketThe myocardial ischemia market is projected to grow from $0.79 billion in 2024 to $1.14 billion by 2030 at a compound annual growth rate of 6.1%, driven by advances in imaging technology, precision medicine, and minimally invasive treatments. In March 2024, Novo Nordisk A/S completed its acquisition of Cardior Pharmaceuticals for approximately €1.025 billion (~$1.10 billion) to strengthen its cardiac portfolio with Cardior's CDR132L drug candidate targeting myocardial ischemia. The report identifies key market segments by type, treatment approach, and end users while profiling leading pharmaceutical and medical device companies operating in the space.openPR.comSegment Analysis and Major Growth Areas in the Heart Failure Medications MarketThe global market for heart failure medications is projected to reach $15.03 billion by 2030, growing at a compound annual growth rate of 6.8%, driven by increasing patient populations, adoption of innovative drug categories, and a focus on personalized cardiovascular care. In March 2024, Novo Nordisk acquired Cardior Pharmaceuticals for $1.112 billion to strengthen its cardiovascular pipeline with Cardior's leading compound CDR132L, currently in phase 2 clinical trials for heart failure treatment. The market report segments the industry by drug class, route of administration, distribution channels, and application areas, listing over 20 pharmaceutical companies as key market participants.Tech.euHTGF: Where public mandate meets venture disciplineHTGF (High-Tech Gründerfonds) is a German public-private venture capital fund combining government backing with VC discipline to support early-stage deep tech, life sciences, and industrial technology startups, operating with approximately 70% public and 30% private capital. The fund has achieved notable exits including Cardior Pharmaceuticals, acquired by Novo Nordisk for up to €1.025 billion, and EGYM, which became a unicorn in 2024 after raising around $200 million. Germany is integrating the DeepTech & Climate Fonds (DTCF) into HTGF to create a unified public-private VC platform spanning seed to growth-stage deep tech, consolidating Germany's fragmented venture funding infrastructure.Market Research FutureWeight Loss Products Market Size, Share, Growth, ReportThe global Weight Loss Products Market is projected to grow from 237.64 billion USD in 2025 to 349.74 billion USD by 2035, driven by rising obesity rates and demand for personalized, technology-enabled solutions. Key industry developments include Eli Lilly's $5.3 billion investment in Zepbound production, Novo Nordisk's acquisition of Cardior Pharmaceuticals, and FDA approvals for new weight-loss therapies.Labiotech.euSeven miRNA-focused companies pioneering new therapies in 2024Seven miRNA-focused biotech companies are advancing therapies in 2024, including aceRNA, ARTHEx, Biorchestra, Cardior, Ceria, Resalis, and TransCode. Their candidates target diseases like cancer, heart failure, and Alzheimer's, with some in phase 1/2 trials. The global miRNA market is projected to grow from $1.58 billion in 2023 to $3.64 billion by 2030.PR NewswireEQT AB (publ) Q1 Announcement 2024EQT AB reported a strong Q1 2024 with total fund commitments exceeding EUR 25 billion, driven by the closings of EQT X (EUR 22 billion) and EQT Future 1 (EUR 3 billion), while fee-generating AUM increased to EUR 132 billion from EUR 119 billion. Investment activity totaled EUR 4 billion including the hyperscale data center partnership with EdgeConneX, the public-to-private tender of Believe, and investment in Avetta, alongside the successful IPO of Galderma on SIX Swiss Exchange raising USD 2.6 billion and gaining over 20% on its first day. Exit activity amounted to EUR 1 billion including sales of CMS Info Systems, Shinhan Financial Group, RBL Bank, Ottobock, and Cardior Pharmaceuticals, though the Wind Tre transaction was terminated; post-period developments include exclusive talks to acquire Ocea Group in France and acquisition of Universidad Europea in Spain and Portugal.Pulse 2.0Novo Nordisk Acquiring Cardior Pharmaceuticals For Up To €1.025 BillionNovo Nordisk agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion, including upfront and milestone payments. The deal includes Cardior's lead compound CDR132L, in phase 2 for heart failure, with a second phase 2 trial planned. Closing is expected in Q2, subject to regulatory approvals.GlobeNewswireNovo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular diseaseNovo Nordisk agreed to acquire Cardior Pharmaceuticals for up to 1.025 billion euros, including upfront and milestone payments. The deal includes Cardior's lead compound CDR132L, in phase 2 for heart failure, with closing expected in Q2 2024. Novo Nordisk will fund the acquisition from financial reserves.Novo NordiskNews DetailsNovo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to 1.025 billion Euros, including upfront and milestone payments, to strengthen its cardiovascular disease portfolio. The deal includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for heart failure, which Novo Nordisk plans to advance through further trials. The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals.